30 Firmen mit Ergebnissen für "limitations"

ETH Entrepreneurship

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18


 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

ETH Entrepreneurship

Wagistrasse 18

8952 Schlieren

789 Ergebnisse für "limitations" unter ETH Entrepreneurship

Swiss Civilian Peace Support: Potential and Limitations

... Swiss Civilian Peace Support: Potential and Limitations CSS Analyses in Security Policy ETH Zurich ... CSS No. 63 • November 2009 SWISS CIVILIAN PEACE SUPPORT: POTENTIAL AND LIMITATIONS For several years ... Swiss Civilian Peace Support: Potential and Limitations ... Swiss Civilian Peace Support: Potential and Limitations CSS Analyses in Security Policy ETH Zurich ... Swiss Civilian Peace Support: Potential and Limitations ...

Cyberwar: Concept, Status Quo, and Limitations

... Cyberwar: Concept, Status Quo, and Limitations CSS Analysis in Security Policy ETH Zurich CSS No ... . 71 • April 2010 CYBERWAR: CONCEPT, STATUS QUO, AND LIMITATIONS Political, economic, and military ... Cyberwar: Concept, Status Quo, and Limitations ... Cyberwar: Concept, Status Quo, and Limitations CSS Analysis in Security Policy ETH Zurich CSS No ... Cyberwar: Concept, Status Quo, and Limitations ...

Mehr Ergebnisse

Somagenetix

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

Somagenetix

Wagistrasse 23

8952 Schlieren

1281 Ergebnisse für "limitations" unter Somagenetix

Labeling surface proteins with high specificity: Intrinsic limitati...

... Labeling surface proteins with high specificity: Intrinsic limitations of phosphopantetheinyl ... Labeling surface proteins with high specificity: Intrinsic limitations of phosphopantetheinyl ... Labeling surface proteins with high specificity: Intrinsic limitations of phosphopantetheinyl ...

Factors explaining limitations in activities and restrictions in pa...

... of activity limitations measured by the Health Assessment Questionnaire (HAQ - model I) and which ... variables with a globally explained variance of 42.4%. CONCLUSION: Activity limitations in RA were mainly ... Factors explaining limitations in activities and restrictions in participation in rheumatoid ... Factors explaining limitations in activities and restrictions in participation in rheumatoid ... Factors explaining limitations in activities and restrictions in participation in rheumatoid ...

Mehr Ergebnisse

University of Zurich

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

University of Zurich

Wagistrasse 12

8952 Schlieren

599 Ergebnisse für "limitations" unter University of Zurich

Opportunities and limitations related to the application of plant-d...

... Jansen, Boris ; Wiesenberg, Guido L B (2017). Opportunities and limitations related to the ... a high diversity of input pathways offering both opportunities and limitations for the use of ... Opportunities and limitations related to the application of plant-derived lipid molecular proxies ... Opportunities and limitations related to the application of plant-derived lipid molecular proxies ... Opportunities and limitations related to the application of plant-derived lipid molecular proxies ...

Prospects and limitations of treatment with botulinum neurotoxin ty...

... Prospects and limitations of treatment with botulinum neurotoxin type A for patients with ... and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic ... Prospects and limitations of treatment with botulinum neurotoxin type A for patients with ... Prospects and limitations of treatment with botulinum neurotoxin type A for patients with ... Prospects and limitations of treatment with botulinum neurotoxin type A for patients with ...

Mehr Ergebnisse

GlycoEra AG

https://glycoera.com/  

8820 Wädenswil, Einsiedlerstrasse 34

 +41 44 733 85 75
 info@glycoera.com

GlycoEra AG is advancing glycoengineered therapeutics to address unmet medical needs. Despite significant advancements in understanding the role of glycans in human health and diseases, this knowledge has not translated well into therapeutic drug development, a consequence of the limitations and complexities of controlling glycosylation processes. GlycoEra’s platform has overcome these challenges! The CustomGlycan Platform enables glycan-mediated modes of action through the engineering of highly defined specific glycan structures, accessing a novel combinatorial dimension for the treatment of very challenging diseases.

GlycoEra AG

Einsiedlerstrasse 34

8820 Wädenswil

1 Ergebnisse für "limitations" unter GlycoEra AG

Home :: GlycoEra

... CustomGlycan platform can overcome the  limitations and complexities of controlling glycosylation through ... address unmet medical needs. GlycoEra’s CustomGlycan platform can overcome the  limitations and ...

Roche Glycart AG

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

Roche Glycart AG

Wagistrasse 10

8952 Schlieren

69 Ergebnisse für "limitations" unter Roche Glycart AG

Hybridization-Based Target Enrichment for NGS

... shortcomings, such as high cost, limitations to the number of samples and large sample requirements. The ... solution-based method overcomes these limitations, while retaining its advantages such as being scalable ... , limitations to the number of samples and large sample requirements. The solution-based method overcomes these ... limitations, while retaining its advantages such as being scalable and easily automatable. In the solution ...

Hybridization-Based Target Enrichment for NGS

... shortcomings, such as high cost, limitations to the number of samples and large sample requirements. The ... solution-based method overcomes these limitations, while retaining its advantages such as being scalable ... (microarray) or in solution. The array-based method has several shortcomings, such as high cost, limitations ... limitations, while retaining its advantages such as being scalable and easily automatable. In the solution ...

Mehr Ergebnisse

LifeMatrix Technologies AG

https://www.lifematrixtechnologies.com/  

8092 Zürich, c/o Wyss Zurich, Weinberstrasse 35

Based in Zurich, Switzerland, LifeMatrix Technologies AG, is a pre-revenue, high-tech startup company spun out of the Institute for Regenerative Medicine at the University of Zurich. Our team combines world leading science in cardiovascular tissue engineering with in-depth entrepreneurial expertise in medical biomimetic device development. The award winning LifeMatrix technology platform is backed by >20 years of research with >150 peer-reviewed publications and a strong patent portfolio. LifeMatrix is currently supported by the Wyss Zurich, a joint accelerator of the University of Zurich and ETH Zurich.

LifeMatrix Technologies AG

c/o Wyss Zurich, Weinberstrasse 35

8092 Zürich

1 Ergebnisse für "limitations" unter LifeMatrix Technologies AG

Technology | LifeMatrix Technologies AG

... to overcome the significant limitations of existing implants.  Award winning bio-engineering platform ... limitations of existing implants.  Award winning bio-engineering platform LifeMatrix Technologies AG c/o Wyss ...

University Hospital Zurich​, Research and Education Office

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

University Hospital Zurich​, Research and Education Office

Rämistrasse 100

8091 Zürich

62 Ergebnisse für "limitations" unter University Hospital Zurich​, Research and Education Office

COPD, emphysema – University Hospital Zurich

... particular interest to us is how the limitations of lung function develop and what impact comorbidities and ... limitations of lung function develop and what impact comorbidities and physical activity have on patients with ...

COPD, emphysema – University Hospital Zurich

... particular interest to us is how the limitations of lung function develop and what impact comorbidities and ... limitations of lung function develop and what impact comorbidities and physical activity have on patients with ...

Mehr Ergebnisse

Swiss Bioscience GmbH

https://www.swissbioscience.com/  

8952 Schlieren, Wagistrasse 27a

 +41 (0) 44 731 99 00
 info@swissbioscience.com

Swiss Bioscience GmbH manufactures and banks stem cells for individuals and provides pharmaceutical grade SVF* and hADSCs** produced under cGMP*** conditions. (* Stromal Vascular Fraction extracted from human lipoaspirate, ** Human Adipose Tissue Derived Stem Cells, *** Current Good Manufacturing Practice)

Swiss Bioscience GmbH

Wagistrasse 27a

8952 Schlieren

2 Ergebnisse für "limitations" unter Swiss Bioscience GmbH

SBS | EVs

... have the limitations of storage. EV-based products can be stored as off-the-shelf products. Diagnostic ... -based products do not have the limitations of storage. EV-based products can be stored as off-the-shelf ...

SBS | Research & Development

... limitations of storage. EV-based products can be stored as off-the-shelf products. Diagnostic and therapeutic ... limitations of storage. EV-based products can be stored as off-the-shelf products. Diagnostic and therapeutic ...

BiognoSYS AG

http://www.biognosys.ch/  

8952 Schlieren, Wagistrasse 21

 +41 44 738 20 40
 info@biognosys.ch

BiognoSYS provides proteomics solutions to scientists and clinicians.

BiognoSYS AG

Wagistrasse 21

8952 Schlieren

6 Ergebnisse für "limitations" unter BiognoSYS AG

PowerPoint Presentation

... consumables (80% and 74%, resp.). [ responses ] 11 Perceived limitations of DIA / SWATH 0% 5% 10% 15% 20% 25 ... , responders that see limitations in “Workflows…” and “Spectral library genera- tion” are less satisfied with ... consumables (80% and 74%, resp.). [ responses ] 11 Perceived limitations of DIA / SWATH 0% 5% 10% 15% 20% 25 ... , responders that see limitations in “Workflows…” and “Spectral library genera- tion” are less satisfied with ...

MRM validation | Biognosys AG

... their limitations when it comes to availability of reagents, multiplexing, specificity, or if results ... antibody reagents have their limitations when it comes to availability of reagents, multiplexing ...

Mehr Ergebnisse

Molecular Partners AG

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

Molecular Partners AG

Wagistrasse 14

8952 Schlieren

5 Ergebnisse für "limitations" unter Molecular Partners AG

About DARPins - Molecular Partners

... believe that DARPins have the potential to overcome many of the limitations that conventional and other ... identify those DARPins that have great potential to overcome a limitations of current therapeutic ... , we believe that DARPins have the potential to overcome many of the limitations that conventional and ... identify those DARPins that have great potential to overcome a limitations of current therapeutic ...

Molecular Partners Reveals Programs in Immuno-Oncology - Molecular ...

... with the potential to overcome the limitations of first-generation approaches,” said Dr. Michael Stumpp ... highly differentiated immuno-oncology therapies with the potential to overcome the limitations of first ...

Mehr Ergebnisse

Mehr Firmen

Nach oben